Get startedLog in
    Picture of Novakand Pharma AB logo

    NOVKAN — Novakand Pharma AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Kancera Reports Positive Results From Final Part Of Phase Ib Program For KAND567

    Picture of Novakand Pharma AB logoNovakand Pharma AB
    06/03/2020 11:49
    March 6 (Reuters) - Kancera AB  KANC.ST :
    * REPORTS POSITIVE RESULTS FROM FINAL PART OF PHASE IB
PROGRAM FOR
KAND567
    * RESULTS FROM PHASE IB PROGRAM FOR KAND567 SHOW THAT DRUG
CANDIDATE IS WELL-TOLERATED BY INTRAVENOUS ADMINISTRATION
    * WILL NOW COMPILE APPLICATION FOR PERMISSION TO START PHASE
II
CLINICAL TRIAL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Source text for Eikon:  ID:nWkrH5PJn 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

    Recent news on Novakand Pharma AB

    See all news